Digital Trials Digest, our quarterly newsletter
One of the keys to optimizing ePRO is deploying artificial intelligence (AI) to support human participants and clinical teams.
The unique challenges associated with women’s health, and women as a cohort, make clinical research in this sector especially difficult. DCTs are helping to tackle the obstacles.
eConsent can mitigate these shortcomings by providing flexibility and engagement that empower patients with information and sponsors with data integrity.
Diversity in clinical trials is a scientific imperative, a moral and ethical necessity—and a longstanding challenge in clinical research. DCTs are evolving the industry status quo.
Combining the ease of ePRO with expert rating—patient convenience with the objectivity of experts—facilitates more accurate data collection.
AI, patient advocacy groups, digital health technologies, and more. Here’s everything you need to know about the clinical trial trends of 2024—and how they’re reshaping the industry.
The FDA’s PFDD guidance series is a much-needed update to the PRO guidance released in 2009. But, what do these new recommendations mean for electronic data capture in clinical trials? Here’s what you need to know.
Artificial intelligence (AI) is transforming the landscape of patient engagement in clinical trials. Here’s everything you need to know.
Virtual clinical trials (VCTs) are a transformative approach to clinical research that's gaining momentum in the life sciences industry.
ePROs, or electronic patient-reported outcomes, play an essential role in clinical trials, illuminating patients' lived experiences.